Bacitracin

證據等級: L5

預測適應症: 10 個

Bacitracin: From Superficial Bacterial Infections to Punctate Epithelial Keratoconjunctivitis

One-Sentence Summary

Bacitracin is a polypeptide antibiotic widely used as a topical agent for superficial bacterial infections of the skin and eyes. The TxGNN model predicts it may be effective for Punctate Epithelial Keratoconjunctivitis, with a prediction score of 99.999%; however, no clinical trials and no publications currently directly support this specific indication, though strong mechanistic reasoning exists based on its established ophthalmic use.

Quick Overview

Item	Content
Original Indication	Superficial bacterial infections (topical antibiotic — skin, eye, wound)
Predicted New Indication	Punctate Epithelial Keratoconjunctivitis
TxGNN Prediction Score	99.999%
Evidence Level	L4 — Mechanistic rationale based on existing ophthalmic use
Malaysia Market Status	✓ Marketed
Number of Registrations	27
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Bacitracin is a cyclic polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. It works by interfering with bacterial cell wall synthesis, specifically by inhibiting the dephosphorylation of the C55-isoprenyl pyrophosphate lipid carrier, which is essential for peptidoglycan synthesis. This gives it potent activity against Gram-positive bacteria including Staphylococcus and Streptococcus species. Due to its nephrotoxicity when given systemically, it is used almost exclusively as a topical agent — in ointments for skin infections, wound care, and ophthalmic preparations.

Punctate epithelial keratoconjunctivitis (PEK) is an inflammatory condition of the cornea and conjunctiva characterised by scattered punctate epithelial erosions. While PEK can arise from viral, allergic, or environmental causes, a significant subset is driven by bacterial infection — particularly Staphylococcus aureus, Moraxella, and other Gram-positive organisms. Bacitracin ophthalmic ointment is already approved and widely used for superficial bacterial eye infections, placing it in direct therapeutic proximity to bacterial PEK.

The mechanistic link is straightforward: Bacitracin’s antibacterial spectrum covers the common pathogens implicated in bacterial PEK, and the ointment vehicle provides an additional benefit of corneal surface lubrication and protection, which aids epithelial healing. This prediction essentially represents a clinical extension of Bacitracin’s existing approved ophthalmic indication rather than a radical drug repurposing — strengthening the plausibility of the TxGNN model’s prediction.

Clinical Trial Evidence

Currently no related clinical trials registered for the specific indication of punctate epithelial keratoconjunctivitis.

Note: Although no trials target this exact indication, Bacitracin ophthalmic ointment has a long history of clinical use in bacterial eye infections, and PEK with a bacterial aetiology falls within its established therapeutic scope.

Literature Evidence

Currently no related literature available for the specific combination of Bacitracin and punctate epithelial keratoconjunctivitis.

Malaysia Market Information

Bacitracin has 27 registered products in Malaysia. Detailed registration information (authorization numbers, product names, dosage forms, and approved indications) was not available in the current data extraction. Bacitracin products are typically available as:

Topical ointments (skin)
Ophthalmic ointments (eye)
Combination products (e.g., with Polymyxin B, Neomycin)

Safety Considerations

Please refer to the package insert for safety information.

Note: Key warnings, contraindications, and drug interaction data are currently pending extraction from the NPRA database and product inserts. It is well-established that Bacitracin carries a risk of nephrotoxicity with systemic use, and topical application may rarely cause contact dermatitis or allergic reactions. Anaphylaxis has been reported in rare cases with topical Bacitracin.

Other Predicted Indications of Interest

Beyond the top-ranked prediction, the TxGNN model identified several other potential indications. The most noteworthy are summarised below:

Rank 4: Otitis Externa (Evidence Level L3)

Item	Detail
TxGNN Score	99.969%
Recommendation	Proceed with Guardrails
Rationale	Bacitracin (often combined with Polymyxin B) is already used clinically for bacterial otitis externa. Gram-positive coverage plus ointment vehicle make it suitable for ear canal infections.

Literature supporting this indication:

PMID	Year	Type	Journal	Key Findings
17503066	2007	Clinical Comparison	Eur Arch Otorhinolaryngol	151-patient RCT comparing Polymyxin B + Bacitracin ointment alone vs. with hydrocortisone for acute otitis externa
14048629	1963	Clinical Study	Z Laryngol Rhinol Otol	Local treatment of inflammatory ear processes with Nebacetin (Bacitracin + Neomycin)
14055264	1963	Clinical Review	Md State Med J	Practical treatment of otitis externa
4306877	1969	Clinical Review	Z Arztl Fortbild	Use of antibiotics in otologic practice
165871	1975	Clinical Study	Can Med Assoc J	Use of trimethoprim-sulfamethoxazole in external otitis
9820118	1998	In vitro / Veterinary	Zentralbl Veterinarmed B	Susceptibility of bacterial isolates from chronic otitis externa to antibiotics including Bacitracin

Rank 2: Exposure Keratitis (Evidence Level L4)

Item	Detail
TxGNN Score	99.991%
Recommendation	Proceed with Guardrails
Rationale	Bacitracin ophthalmic ointment is already part of standard clinical practice for exposure keratitis — providing both antibacterial prophylaxis against secondary infection and physical corneal lubrication/protection through the ointment base.

Indications Recommended as Hold

Rank	Disease	TxGNN Score	Reason for Hold
3	Non-human animal disease	99.970%	Not applicable to human medicine
5	Postinfectious vasculitis	99.968%	No mechanistic link; topical agent cannot treat systemic vasculitis
7	Infective urethral stricture	99.965%	Topical formulation cannot reach target; primary pathology is fibrosis, not infection
8	Post-infectious syndrome	99.965%	Overly broad category; no anti-inflammatory or immunomodulatory activity
9	Infection-related HUS	99.962%	Antibiotic use may worsen STEC-associated HUS; topical agent cannot treat systemic disease
10	Chagas cardiomyopathy	99.961%	Caused by protozoan (T. cruzi); antibacterial agent has zero activity against parasites

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The top-ranked prediction (punctate epithelial keratoconjunctivitis) is highly plausible because Bacitracin ophthalmic ointment is already approved and used for superficial bacterial eye infections — PEK with bacterial aetiology is a natural therapeutic extension. The otitis externa indication (rank 4) is supported by published clinical comparison data. Both represent low-risk expansions of existing clinical use rather than radical repurposing.

To proceed, the following is needed:

Detailed mechanism of action data from DrugBank (currently a data gap)
NPRA product insert safety information including warnings, contraindications, and precautions
Extraction of detailed Malaysia registration data (authorization numbers, product names, dosage forms, approved indications) for the 27 registered products
Clinical review to confirm that PEK indication is not already covered by existing approved ophthalmic indications (may be a labelling gap rather than true repurposing)
For otitis externa: systematic review of existing evidence including the Mösges et al. 2007 clinical comparison study

This report is for research purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application. Data cutoff: 2026-04-09.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.